Healthcare / BiotechnologyShanghai
$9.48
-0.21 (-2.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $58.4M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
67.7x
↑EV/EBITDA
31.7x
↑ROE
5.8%
↑Gross Margin
53.5%
↑Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.2%
FCF CAGR
—
FCF margin
6.6%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $792.8M · net income $130.6M · FCF $52.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $792.8M | $792.8M | $795.3M | $816.8M | $764.5M |
| Net Income | $130.6M | $130.6M | $206.8M | $253.9M | $235.4M |
| EBITDA | $220.2M | $220.2M | $311.6M | $339.4M | $296.4M |
| EPS | 0.16 | 0.16 | 0.25 | 0.31 | 0.29 |
| Gross Margin | 53.5% | 53.5% | 54.2% | 55.0% | 51.5% |
| Operating Margin | 17.5% | 17.5% | 25.9% | 32.1% | 28.0% |
| Net Margin | 16.5% | 16.5% | 26.0% | 31.1% | 30.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.12 | 0.14 | 0.17 |
| Current Ratio | 2.64 | 2.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $52.1M | $52.1M | $66.6M | $58.4M | $-151.3M |
| Returns | |||||
| ROE | 5.8% | 5.8% | 9.1% | 11.9% | 16.1% |
| Valuation | |||||
| P/E | 67.71 | 67.71 | 41.76 | 29.06 | 42.63 |
| EV/EBITDA | 31.66 | 31.66 | 25.07 | 19.32 | 32.61 |
| P/B | 3.41 | 3.41 | 3.80 | 3.44 | 6.87 |
| Growth & Yield | |||||
| Revenue Growth | -0.3% | -0.3% | -2.6% | 6.8% | — |
| EPS Growth | -36.0% | -36.0% | -19.4% | 5.9% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
73.9%
EPS terminal req.
$0.84
Spread vs growth
-109.9%
5Y implied EPS CAGR
44.8%
EPS terminal req.
$1.02
Spread vs growth
-80.8%
10Y implied EPS CAGR
26.2%
EPS terminal req.
$1.64
Spread vs growth
-62.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.2%
Start / end P/E
33.5x → 59.2x
EPS bridge
0.25 → 0.16
Residual
-27.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.